Design and Biological Activity of (<i>S</i>)-4-(5-{[1-(3-Chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-Aminopyrrolidinone Farnesyltransferase Inhibitor with Excellent Cell Potency

Ian M. Bell(United States Military Academy), Theresa M. Williams(United States Military Academy), Robert B. Lobell(United States Military Academy), Marc Abrams(Dicerna Pharmaceuticals (United States)), Nancy E. Kohl(United States Military Academy), George D. Hartman(Joint BioEnergy Institute), Patricia A. Miller(United States Military Academy), Samuel Graham(Georgia Institute of Technology), Joseph Culberson(United States Military Academy), W. Wayt Gibbs(United States Military Academy), Joel R. Huff(United States Military Academy), Carl F. Homnick(United States Military Academy), Eileen S. Walsh(Janssen (Switzerland)), Joseph J. Lynch(United States Military Academy), Carolyn A. Buser(United States Military Academy), Kelem Kassahun(United States Military Academy), Kenneth S. Koblan(Sumitomo Dainippon Pharma (United States)), Douglas C. Beshore(United States Military Academy), Steven N. Gallicchio(United States Military Academy), Joseph P. Davide(United States Military Academy), A. David Rodrigues(Bristol-Myers Squibb (Germany)), Charles A. Omer(United States Military Academy), Michelle Ellis-Hutchings(United States Military Academy), Christine Fernandes(United States Military Academy), David Heimbrook(United States Military Academy)
Journal of Medicinal Chemistry
July 31, 2001
Cited by 43


Related Papers